中触媒新材料股份有限公司 2026 年第一次临时股东会 之 法律意见书 上海市静安区山西北路 99 号苏河湾中心 MT 25-28 层 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai, China 电话/Tel: +86 21 5234 1668 传真/Fax: +86 21 5234 1670 网址/Website: http://www.grandall.com.cn 国浩律师（上海）事务所 关 于 2026 年 2 月 国浩律师（上海）事务所 法律意见书 国浩律师（上海）事务所 关于 中触媒新材料股份有限公司 2026 年第一次临时股东会之 法律意见书 致：中触媒新材料股份有限公司 国浩律师（上海）事务所（以下简称"本所"）接受中触媒新材料股份有限 公司（以下简称"公司"）委托，指派本所律师出席公司 2026 年第一次临时股 东会（以下简称"本次股东会"）。本所根据《中华人民共和国证券法》（以下 简称"《证券法》"）、《中华人民共和国公司法》（以下简称"《公司法》"）、 《上市公司股东会规则 ...

证券代码：688267 证券简称：中触媒 公告编号：2026-004 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2026 年 2 月 26 日 中触媒新材料股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （二） 股东会召开的地点：辽宁省大连普湾新区松木岛化工园区中触媒新材料 股份有限公司学术报告厅 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 76 | | --- | --- | | 普通股股东人数 | 76 | | 2、出席会议的股东所持有的表决权数量 | 87,056,981 | | 普通股股东所持有表决权数量 | 87,056,981 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 50.2868 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 50.2868 | ...

证券代码：688267 证券简称：中触媒 公告编号：2026-005 中触媒新材料股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计， 具体数据以中触媒新材料股份有限公司（以下简称"公司"）2025年年度的定期 报告为准，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 单位：人民币 万元 | 项目 | 本报告期 | 上年同期 | 增减变动幅 | | --- | --- | --- | --- | | | | | 度（％） | | 营业总收入 | 85,572.27 | 66,660.88 | 28.37 | | 营业利润 | 24,364.93 | 16,646.34 | 46.37 | | 利润总额 | 24,201.18 | 16,421.61 | 47.37 | | 归属于母公司所有者的净利润 | 21,181.08 | 14,552.48 | 45.55 | | 归属于母公司所有者的扣除非 ...

中触媒发布业绩快报，2025年度营业总收入8.56亿元，同比增长28.37%；净利润2.12亿元，同比增长 45.55%。报告期内，随着精细化工行业的稳步复苏，公司紧抓市场机遇，依托持续的研发创新，成功 将多项研发成果实现工业化转化，进一步丰富了催化新材料产品线；钛硅系列催化剂（应用于己内酰 胺、环氧丙烷等）成功开拓新市场与新客户，销量实现显著增长。同时，公司积极拓展市场，在尾气治 理等环保领域的市场占有率稳步提升，移动源脱硝分子筛等产品销量大幅增长，吡啶合成催化剂等精细 化工产品亦呈现稳定增长态势。此外，部分原材料及能源价格同比有所下降，也为公司利润增长贡献了 积极因素。 ...

格隆汇2月25日｜有投资者在互动平台向中触媒提问：公司特种分子筛和催化剂营收占了主营绝大部 分，除此之外，近年公司在新材料研发和应用上有什么重大的、新的突破吗？ 中触媒回复称，近年公司持续加大研发投入强度，丰富产品矩阵，拓展产品应用与新材料领域，其中公 司已掌握人工合成高纯石英砂的全套生产工艺和合成核心技术，相关核心工艺已完成中试阶段的验证与 定型，纯度可达到5N以上；公司高纯氧化铝项目处于试生产阶段，纯度可达到5N。具体项目进展情况 请您关注公司后续披露的定期报告。 ...

Group 1 - The core viewpoint of the article highlights that Zhong Chumai has announced a delay in its "Environmental New Materials and Intermediates Project" to 2028, citing industry technology trends, market demand changes, and optimization of approval processes as reasons for the delay [1] - The company has confirmed that it has mastered the complete production process for artificial high-purity quartz sand and completed pilot testing, but there are still risks related to technological scaling and market competition in the industrialization process [1] - Zhong Chumai clarified that the construction of its iron-molybdenum catalyst production line is funded by its own capital, not through raised investment funds, to avoid overcapacity [1] Group 2 - In the recent stock performance, Zhong Chumai's share price experienced slight fluctuations, with a cumulative increase of 0.94% over the past week, closing at 29.00 yuan on February 9, 2026 [2] - The main capital flow showed a net outflow of funds over the past five days, with notable outflows on February 10 and February 11, while there was a net inflow on February 12 [2] - Institutional ratings indicate that in the past 90 days, three institutions have covered Zhong Chumai, with two giving a "Buy" rating and one an "Add" rating, reflecting market recognition of its business prospects [3]

证券代码：688267 证券简称：中触媒 中触媒新材料股份有限公司 2026 年第一次临时股东会会议资料 中触媒新材料股份有限公司 2026 年第一次临时股东会 会议资料 2026 年 2 月 中触媒新材料股份有限公司 2026 年第一次临时股东会会议资料 目录 | 2026 年第一次临时股东会会议须知 | 3 | | --- | --- | | 2026 年第一次临时股东会会议议程 | 6 | | 议案一：关于部分募投项目结项并将节余募集资金永久补充流动资金、 | | | 部分募投项目内部投资结构调整及延期的议案 7 | | 中触媒新材料股份有限公司 2026 年第一次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效 率，保证会议的顺利进行，根据《中华人民共和国公司法》、《中华人 民共和国证券法》、《上市公司股东会规则》以及《中触媒新材料股份 有限公司章程》、《中触媒新材料股份有限公司股东会议事规则》的相 关规定，特制定本会会议须知： 一、公司建议股东及股东代表采用网络投票方式参加本次股东会， 为确认出席会议的股东或其代理人或其他出席者的出席资格，会议工 作人员将对出席会议者的身 ...

Core Viewpoint - The company has completed the "Iron Molybdenum Catalyst Synthesis Technology Development" project and will focus on more urgent projects to avoid overcapacity [1] Group 1 - The company announced that the project related to iron molybdenum catalyst synthesis has been concluded and will be disclosed in the 2024 annual report [1] - The expansion of production lines is funded by the company's own resources and is being carried out on existing production lines [1] - The current production capacity is sufficient to meet market demand, leading the company to redirect funds to more pressing projects [1]

Investment Rating - The report assigns a rating of "Buy" for the company [5][12]. Core Insights - The company specializes in the research, production, and sales of specialty molecular sieves and catalytic new materials, with ongoing projects laying a foundation for future growth [2][20]. - The projected earnings per share (EPS) for 2025, 2026, and 2027 are estimated to be 1.16, 1.39, and 1.66 yuan respectively, with a target price set at 34.75 yuan based on a 25x PE valuation for 2026 [17][12]. - The company has established a comprehensive core process technology system covering the entire chemical industry chain, successfully developing multiple proprietary technology packages [12][20]. Financial Summary - Total revenue is projected to grow from 550 million yuan in 2023 to 1,528 million yuan in 2027, reflecting a compound annual growth rate (CAGR) of approximately 30.6% [4][13]. - Net profit attributable to shareholders is expected to increase from 77 million yuan in 2023 to 293 million yuan in 2027, with a significant rebound in 2024 showing an 89.2% increase [4][13]. - The company’s net asset return rate is projected to rise from 2.9% in 2023 to 8.9% in 2027, indicating improving profitability [4][13]. Production Capacity and Utilization - The company plans to increase its production capacity for specialty molecular sieves and catalysts by 3,000 tons in 2025 and an additional 3,300 tons by February 2026 [18][12]. - The utilization rates for the specialty molecular sieves and catalysts series are estimated to be 72%, 64%, and 77% for the years 2025 to 2027 respectively [18]. Market Position and Competitive Analysis - The company is positioned within the specialty molecular sieve industry, with comparable companies such as Jianlong Micro-Nano and Kaili New Materials showing an average PE of 23x for 2026 [19][17]. - The report emphasizes the strategic importance of the company's products in energy conservation and environmental protection, highlighting its role in the emerging materials sector [20].

Investment Rating - The report assigns a rating of "Buy" for the company [5][12]. Core Insights - The company specializes in the research, production, and sales of specialty molecular sieves and catalytic new materials, with ongoing projects laying a foundation for future growth [2][20]. - The projected earnings per share (EPS) for 2025, 2026, and 2027 are estimated to be 1.16, 1.39, and 1.66 yuan respectively, with a target price set at 34.75 yuan based on a 25x PE valuation for 2026 [12][17]. - The company has established a comprehensive core process technology system covering the entire chemical industry chain, successfully developing multiple proprietary technology packages [12][20]. Financial Summary - Total revenue is projected to grow from 550 million yuan in 2023 to 1,528 million yuan in 2027, reflecting a compound annual growth rate (CAGR) of approximately 30.6% [4][13]. - Net profit attributable to shareholders is expected to increase from 77 million yuan in 2023 to 293 million yuan in 2027, with a significant rebound in 2024 showing an 89.2% increase [4][13]. - The company’s net asset return rate is projected to rise from 2.9% in 2023 to 8.9% in 2027, indicating improving profitability [4][13]. Production Capacity and Utilization - The company plans to increase its production capacity for specialty molecular sieves and catalysts by 3,000 tons in 2025 and an additional 3,300 tons for environmental catalysts by February 2026 [18][20]. - The expected capacity utilization rates for specialty molecular sieves and catalysts are projected to be 72%, 64%, and 77% for 2025, 2026, and 2027 respectively [18]. Comparable Company Valuation - The report compares the company with peers in the molecular sieve industry, with an average PE of 23x for 2026 among comparable companies [17][19].